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tions on epidemiological data; 12 specified that the uncertainty surrounding epi-
demiological data should be addressed, especially in terms of the transferability of
international data. The party responsible for the conduct of the analysis (therefore
responsible for providing the epidemiological data) was named by 20 guidelines, of
which 14 explicitly referred to the marketing authorization holder. Furthermore,
an acceptable level of evidence was mentioned only by 4 guidelines (Australia,
Austria, Poland, and Scotland) and included surveys, registers, databases and ex-
perts’ opinions. The relevance of epidemiological data for final reimbursement
decisions was explicitly mentioned by 5 guidelines (Australia, Israel, Russia, Scot-
land, and South Africa). However, consequences for unacceptable epidemiological
evidence (i.e., cases not following recommendations or requirements) were only
indicated by Russia and Scotland in the form of refraining from giving positive
reimbursement advice. CONCLUSIONS: Population-level epidemiological data is
mentioned in 77% of the guidelines, but those focus mostly on issues of data trans-
ferability. Only few countries (19%) address the role of population-level epidemio-
logical data for reimbursement decisions. To reduce decision uncertainty, ap-
proaches to address the often occurring paucity of epidemiological evidence
should preferably be part of all pharmacoeconomic guidelines.
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OBJECTIVES: We investigated commonalities and significant differences in HTA
evidence requirements in the EU5 (Germany, France, UK, Italy and France) and the
implications on phase III programmes, focusing on three key, rapidly evolving
elements of HTA: choice of the comparator, Health-Related Quality of Life (HRQL)
and effectiveness. METHODS: In-depth, semi-structured 60-min telephone inter-
views were undertaken with 34 HTA experts across the EU5 (17 from HTA bodies
and Academia, 17 from pharma). RESULTS: An active comparator in phase III is
mandated or clearly preferred in all EU5 countries for HTA/payer purposes. It tends
to be the therapy most commonly used in clinical practice, although best practice
or cheapest therapy may be selected. Countries vary in the degree of flexibility in
the approach to comparative evidence. UK appears to be the most flexible in the
choice of comparator and acceptance of indirect evidence. Germany is the most
demanding (e.g. head-to-head data vs. multiple, specific comparators for multiple
sub-populations). HRQL is increasingly important in HTA, yet all respondents
agreed that, in practice, HRQL is still only supportive to ‘hard’ end-points such as
morbidity and mortality. Challenges in capturing HRQL as a measure of clinical
benefit and/or a way to derive utilities, were discussed. Demonstrating effective-
ness is becoming increasingly relevant to HTA, although efficacy data from phase
III trials still have the major role – the greatest challenge is the generalisation of
results to the wider, real-world patient population. Countries differ in their flexi-
bility to addressing the demonstration of effectiveness. CONCLUSIONS: Increased,
and sometimes contradictory, HTA-driven demands for evidence place strain on
phase III trials. Hopefully, as Germany, the UK and France .adapt their processes,
and Spain and Italy develop fuller capability, harmonisation of core HTA require-
ments will enable pharma to design more efficient evidence programmes. Sugges-
tions derived from this research will be presented.
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OBJECTIVES: It is often considered that the UK grants access to new medicines
upon marketing authorisation (MA) approval, while patients in countries such as
France or Belgium gain access only after significant delays. The objective is to
quantify differences in time to market access between the UK (excluding Scotland),
France and Belgium and to identify contributing factors. METHODS: We reviewed
submission and approval dates for all new chemical or biological entities that were
granted a MA by the European Commission (EC) between August 2006 and July
2011. Generics, fixed dose combinations, new formulations, and vaccines were
excluded. Information was collected from official health authority sources (i.e.
regulatory, health technology assessment, and pricing agencies; official journals;
national formularies). Results are presented as median days pre- and post-market-
ing authorisation (MA was defined as day 0). RESULTS: For the 111 drugs we iden-
tified, EC approval was granted a median of 428 days after submission of the ap-
plication and 64 days after the Committee for Medicinal Products for Human Use
issued a positive opinion. A first analysis suggested more drugs were marketed in
England (n97), than in France (n74) or Belgium (n62). NICE guidance, however,
was only issued for 29 products (21 positive opinions) after a median of 399 days
following MA. In France and Belgium, ministerial reimbursement decisions were
published in the Official Journal after 279 and 348 days, respectively. The time
needed for Belgian companies to submit a reimbursement dossier was variable
(median: 68 days; IQR: 21-235 days after MA). CONCLUSIONS: As product uptake is
negligible until NICE issues a positive guidance, English patients have access to
only a limited number of innovative drugs. French authorities appear to grant
access to more products and have shorter review timelines than their Belgian and
English counterparts. Dossier submission timelines may contribute to delays in
Belgium.
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OBJECTIVES: Describe and analyze the impact of the recognition of the Economic
and Public Health Assessment Committee (CEESP) as an official committee, part of
the French National Authority for Health (HAS), within the new code of social
security for drug market access. METHODS: We browsed website of French gov-
ernment, reviewed grey literature relating to the introduction of health economic
criteria in the recommendations of the CEESP and interviewed decison makers.
RESULTS: The remit of CEESP is to determine efficient strategies and edit recom-
mendations to support price negotiations. Products eligible for economic assess-
ment will be selected based on criteria to be defined and some areas of uncertainty
remain to be addressed. (1) Criteria for product selection: all products that state
innovative improvement, product with sales above €10 million per year, new mode
of action and products with potential extension of target population are likely to be
assessed; orphan designated product are not. At time of approval, the scope of
assessment will be relatively narrow and outstanding questions addressed during
reassessments 3 to 5 years later. (2) How the Transparency Committee (TC) and
CEESP will resolve divergent opinions: While TC only focus on clinical trials, CEESP
is expected to have a broader perspective. As both committees operate indepen-
dently, it is urgent that a clear process is established to clarify the resolution of
divergent opinion. (3) Methodology used for economic assessment: HAS published
guidelines for economic analysis. They remain very flexible even if some specific
recommendations were made (e.g. no cost benefit analysis, loss of productivity not
included in reference case, deterministic and probabilistic sensitivity analysis re-
quired). Finally no information is available to inform how CEEPS opinion will im-
pact pricing negotiation. CONCLUSIONS: Although application decrees are still to
be issued, there are important areas of uncertainty surrounding introduction of
health economics in market access of drugs in France.
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OBJECTIVES: Compared to small molecule generics, biosimilars have different
price drivers due to greater manufacturing complexity and stronger regulatory
hurdles. We looked to investigate historic trends in biosimilars pricing and assess
what may change in the future. In addition, we aimed to understand how the
recent FDA guidelines will shape pricing of biosimilars in the US. METHODS: In
order to understand the historic trends shaping biosimilars pricing, we conducted
secondary research into the pricing of 14 biosimilars in EU5 markets. Focusing on
qualitative analysis, we assessed three potential factors that shape current pricing:
1) Launch date; 2) Number of biosimilars available; and 30 Therapy area. Primary
research was conducted by surveying a selection of payers in order to understand
the current price drivers and how these will potentially change in the future. We
also assessed their expectations on how FDA pathway regulations will affect pric-
ing in the US. RESULTS: Historical analysis of biosimilar pricing indicated similar
pricing across the sample, with average pricing at a 20-30% discount relative to the
originator. These results indicated no significant correlation between the number
of biosimilars available, launch date or therapy area, suggesting that common
drivers such as development and manufacturing costs shape pricing across ther-
apy areas. Payers noted that future manufacturing costs (particularly for monoclo-
nal antibodies), regulatory hurdles, and phase IV trial requirements will maintain
upward pressure on biosimilar prices, but increasing competition over time would
likely bring down prices relative to originators. CONCLUSIONS: Historically, bio-
similar pricing has been driven by the date of launch and therapy area, in addition
to the high R&D costs of manufacturing. Predictions for the future indicate that
biosimilars pricing will maintain current levels due to competing pressures. Payers
in the US foresaw similar pricing trends, but did not expect as great a level of
discounting seen in the EU.
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OBJECTIVES: The social security system in Greece was characterized complex and
fragmented and unlike other countries, the existence of many insurance agencies
did not create any competition in the health system. In March 2011, the National
Organization for the Provision of Health Care (EOPYY) was established. The aim of
the study was to highlight stakeholder’s insights on the establishment of EOPYY
and their perceptions for the applicability of the reform. METHODS: A qualitative
study, using the method of semi-structured interviews was conducted using an
open-ended questions guide. In order to identify stakeholders at the very top of the
‘power’ list (decision makers) as well as people and groups whose opinion matters
in shaping reform policies (opinion leaders), we undertook a stakeholder mapping
and 24 targeted stakeholders were found. In total 17 interviews were conducted,
tape recorded, transcribed and content analyzed. RESULTS:According to the inter-
viewees, the setting-up of EOPYY was considered necessary and valuable, taking
into consideration that it will contribute to the consolidation of the benefits and the
enhancement of the Welfare State, the establishment of a modern system of pri-
mary health care and the enhancement of its negotiation power. Regarding the so
far implementation of the reform, stakeholders have reservations and are skeptical
about the specific goals and the orientation of the Organization. Notably, concerns
were focused on the reimbursement method of the doctors, on the selection crite-
ria and on the lack of a specific mission. CONCLUSIONS: Although, the stated
objectives of the implementation of EOPYY appear positive and ambitious, the
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restraints and objections about the viability of the fund are still a matter of debate,
focused particular on the development of a flexible mechanism for primary health
care that will ensure equitable access and benefits for members and improve the
quality of services.
PHP136
GENERIC PRICE LINKAGE AS A POLICY CHOICE: REVIEW OF RECENT
DEVELOPMENTS
Izmirlieva M1, Ando G2
1IHS, London, UK, 2IHS Global Insight, London, UK
OBJECTIVES: Price capping of generics against the originator (also known as price
linkage) has been in use for some time despite studies questioning its efficacy as a
cost-containment mechanism. In particular, a 2007 study from Norway – where
internal reference and generic price linkage to the originator co-existed for some
time - found that both originator and generic prices fell significantly, but the price
decline impact was sharper for originator drugs in the reference pricing group than
in the price caps group. This study seeks to evaluate if price capping remains a
policy of choice in the current austerity climate. METHODS: Research focused on a
review of current pricing and reimbursement (P&R) regulations for generics in
European Union countries and major markets outside the EU to identify which
countries have adopted or are in the process of adopting new price caps or have
amended existing price caps for generics versus the originator from the start of
2010 to date. The review includes both original laws related to price capping and
interpretation of the place of price linkage in each country’s pharmaceutical P&R
system from secondary sources and from IHS Global Insight’s proprietary Same
Day Analysis archive. RESULTS: France, Portugal, Hungary, the Czech Republic,
Romania, Slovakia, Greece, Japan and Canada are among the countries which have
recently amended their use of price linkage in an attempt to contain pharmaceu-
tical spending.CONCLUSIONS:While price caps remain popular, it is rare for coun-
tries to use them in isolation. Internal reference pricing is typically also in use.
Among countries which have recently made changes to their price linkage system,
Romania, Hungary and Poland have also undertaken changes to their internal
reference pricing system, as governments attempt to tackle the cost-containment
paradigm from all sides.
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OBJECTIVES: To analyze the influence of regulatory changes for medicines pricing
and reimbursement on medicines prices. METHODS: Regulatory analysis was per-
formed towards the Drug Law, Regulation on positive drug list (PDL), and on med-
icines reimbursement rules. All medicines affected by the changes were system-
ized by the way of dispensing and financing. Comparative analysis of the changes
in medicines prices before and after 30 of March 2011 was developed as well a year
later for absolute and relative change of the prices. RESULTS: The pricing and
reimbursement processes are controlled by the Pricing and reimbursement com-
mittee within MoH. Medicines are separated in two groups according to their price
control – with registration of maximal retails prices for OTC and out of the reim-
bursement list (30 days procedure); and regulation of prices for publicly financed
medicines (60 days procedure) by inclusion into the PDL. In the beginning of 2011
the Ministry council initiated regulatory changes. 150 INN of medicines that were
financed via the centralized procurement procedures organized by the MoH were
separated in 2 groups. 82 INN for outpatient care were transferred to national
health insurance fund (NHIF) and 68 for inpatient care to hospitals. For the 82 INN
were changed not only the procurement and financing institution but also the way
of prices establishment through regulated as reference prices with regressive mar-
gins. Only 5 medicines decrease their prices after the transformation, but a year
later all medicines decreased their prices. For the medicines transferred to hospi-
tals the biggest hospitals managed to contract lower prices than before but small
ones were unable to do so. In general total cost of the supplied medicines weighed
by quantity procured was lower than before the changes. CONCLUSIONS: Regula-
tory changes led to positive economic impact but still the long term consequences
remain unclear for all medicines.
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OBJECTIVES: Patient access schemes (PAS) are commonly used in the UK as a way
to reduce a drug’s Incremental Cost Effectiveness (ICER) per Quality Adjusted Life
Year (QALY) ratio and gain NICE acceptance without reducing the list price. With
the advent of value based pricing (VBP) in 2014, the role of PAS is expected to
change. This study examines if PAS will continue to be used in the UK after VBP is
introduced and what their role is likely to be. METHODS: Stakeholders involved in
the current NICE health technology assessment process were interviewed to un-
derstand how PAS use may evolve following the introduction of VBP. Secondary
research was conducted of government proposals for VBP implementation, the
NICE response to VBP consultation and the current usage of PAS in the UK based on
NICE assessments and data from the IHS Global Insight Risk Sharing database.
RESULTS: With the advent of VBP, the price of a drug should in principle reflect its
value taking into account the level of uncertainty related to its efficacy. All drugs
that pass the VBP test should, in theory, be reimbursable, thus, eliminating the
need for a PAS that adjusts the cost of treatment allowing it to meet the UK’s ICER
per QALY threshold. Contrary to these expectations, primary research indicates
that PAS would continue to be used as payers attempt to secure a price lower than
the NICE-set VBP. CONCLUSIONS: PAS would remain a fact of life in the UK even
after VBP is implemented. This would apply not only for older drugs launched
before VBP, but also for new drugs and new indications marketed post-2013 be-
cause payers are expected to see the NICE-established VBP as a recommended
maximum price and attempt to negotiate that down through a PAS.
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OBJECTIVES: Defining and applying decision criteria are key to accountability and
reasonableness in decisionmaking and to ensure the most beneficial allocation of
health care resources. Objectives were to gather data on criteria considered by
policy and clinical decisionmakers in health care decisions globally.METHODS:An
online questionnaire was developed with 43 criteria organized into 10 clusters.
Using snowball sampling, decision makers were invited by an international task
force to report which criteria they consider and how these criteria weighed when
making decisions on health care interventions in their context. For each criterion,
respondents reported “currently considered”, “should be considered” and weight
assigned. Differences in proportions of participants reporting consideration of
each criterion were explored with inferential statistics across levels of decision
(micro, meso, macro), decision-maker perspective, and world region. RESULTS: A
total of 140 decision makers (1/3 clinical, 2/3 policy) from 23 countries in five con-
tinents completed the survey. Most relevant criteria (top ranked for “Currently
considered”, “Should be considered” and weights) were Clinical efficacy/effective-
ness, Safety, Quality of evidence, Disease severity and Impact on health care costs.
Organizational and skill requirements ranked high for consideration but low for
weights. For a majority of criteria, the number of decision makers reporting that
they ‘should be considered’ was higher than that reporting they are currently con-
sidered (P0.05). For more than 75% of criteria, there were no statistical differences
in proportions across levels of decision, perspective and world region. Differences
in proportions across several comparisons were statistically significant for criteria:
Population priorities, Stakeholder pressure/interests, Capacity to stimulate re-
search, Impact on partnership and collaboration, and Environmental impact
(P0.05). CONCLUSIONS: Results suggest a significant international agreement
among decision makers on the relevance of a core set of normative and feasibility
criteria and on the need to consider a wider range of criteria in decision-making
processes. Areas of divergence appear to be principally related to contextual as-
pects.
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OBJECTIVES: Since 2011, pharmaceutical companies have to submit a benefit as-
sessment dossier for new drugs in Germany. The dossier must contain information
about the additional benefit to an appropriate comparative therapy (ACT), costs
and the potentially targeted patient population. This work’s aim is to display the
challenges in collecting the information for Xiapex®, approved for treatment of
Dupuytren’s contracture in patients with a palpable cord, which was compared to
limited fasciectomy.METHODS:A systematic literature review, national and inter-
national, was used to determine epidemiological figures and cost data. Where no
information was available, necessary data was assessed from claim data. To deter-
mine the percentage of patients with palpable cord a Delphi study was conducted
with office based hand surgeons and orthopaedists. RESULTS: No valid data basis
was found for national epidemiological figures. Estimations based on European
prevalence data (1,7%-2,4%) lead to 1,34-1,9 Mio. Germans affected by Mb. Du-
puytren. Thereof, approx. 35.800 surgeries are conducted in Germany per year. The
Delphi-study revealed an estimation of 53,5% patients with palpable cord, resulting
in 19.153 patients eligible to Xiapex® treatment. No literature was found for treat-
ment costs of Mb. Dupuytren. Actual costs (inpatient and outpatient care plus
additional costs) were therefore selected from available claim data resulting in a
weighted average of 2087,58€ per patient and year. CONCLUSIONS: With a surgical
procedure as ACT, dossier developers have to face challenges due to the lack of
transparent, publically available data. Best available sources were used to gather
the information needed. The fact that the German IQWiG challenged our data
within the benefit assessment process without being able to provide better sources
of information underlines the necessity of an improvement regarding the availabil-
ity and open access to suitable data. This will increase validity of data in the
required dossier for an informed consequent decision making.
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EFFECTS OF CHANGING HEALTH POLICY ON PHARMACOECONOMICS AND
HEALTH OUTCOME STUDIES IN TURKEY
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